First FDA-Approved CBD Medication to Cost More than $32,000 Per Year

GW Pharmaceuticals has revealed the expected consumer price for Epidiolex, the first cannabidiol-based medication to be approved by the FDA, according to a Business Insider report. At a price tag of about $32,500 per year, it won’t be cheap, but company representatives said in a phone call with investors this week that its cost reflects that of […]

Read More - -

Tags: , , , ,

California to Block Hemp-Derived CBD From All Food Products

The California Department of Public Health’s Food and Drug Branch (CDPH-FDB) updated an FAQ last week to address food products containing hemp-derived CBD and — according to a Canna Law Blog report — it could completely upend the state’s well-established and diverse CBD product marketplace. “Although California currently allows the manufacturing and sales of cannabis products […]

Read More - -

Tags: , ,

FDA Approves CBD-Based Epidiolex

The Food and Drug Administration approved GW Pharmaceuticals’ cannabidiol-based medication Epidiolex on Monday, according to the Washington Post. It is the first cannabis-based medication to be federally allowed in the United States. Epidiolex is an oral solution that utilizes CBD and was designed to treat two severe but rare forms of epilepsy. The drug was approved for […]

Read More - -

Tags: , , ,

McConnell’s Bill Would Normalize the Hemp Industry

Last week, Senate Majority Leader Mitch McConnell (R-KY) took to the chamber floor and laid out his case for the Hemp Farming Act of 2018, calling hemp a cash crop for the nation’s struggling farmers, a modernization of federal law, a “new spark” for the U.S. economy. McConnell was also the driving force securing the […]

Read More - -

Tags: , , , , , , ,

Epidiolex Receives Initial Recommendation from FDA Committee

Epidiolex, a CBD-based pharmaceutical medication created by GW Pharmaceuticals in the United Kingdom, has received a unanimous recommendation from an FDA advisory committee. The committee’s recommendation sets Epidiolex up to potentially receive FDA approval for U.S. distribution by June, CNN reports. According to GW’s website, Epidiolex is a “proprietary oral solution of pure plant-derived cannabidiol.” It was developed […]

Read More - -

Tags: , ,

NORML Launches Website to Send FDA Public Comments Regarding Cannabis Rescheduling

The Food and Drug Administration is asking for public comment on the international scheduling of cannabis following a request from the World Health Organization. “The Food and Drug Administration (FDA) is requesting interested persons to submit comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use […]

Read More - -

Tags: , , , ,

Massachusetts Alcohol Regulators Block CBD Beer Claiming FDA Rules Violation

The Massachusetts Alcoholic Beverage Control Commission will not allow a local brewer to move forward with plans to roll out a CBD-infused beer, arguing that the cannabinoid is a Schedule I drug and the infusion would violate the Food & Drug Administration’s Food, Drug and Cosmetic Act, the Boston Business Journal reports. “Even though retail […]

Read More - -

Tags: , , , ,

MMJ Research Firm Secures Production License from Health Canada; One Step Closer to FDA Approval

MMJ Bioscience is in the process of securing orphan drug status from the U.S. Food & Drug Administration for MMJ 001, a CBD derivative, for use as a multiple sclerosis therapy. The company has secured a Health Canada license to produce cannabis for medical purposes to extract active ingredients from cannabis to manufacture gelcaps and […]

Read More - -

Tags: , , ,

FDA Requests Public Comments on Therapeutic Value of CBD

The U.S. Food and Drug Administration (FDA) has put out a call for public comments regarding the therapeutic values and potential for abuse of several substances, including cannabidiol or CBD. According to a document released by the FDA, the agency will consider any submitted statements while preparing their response to the World Health Organization (WHO) regarding […]

Read More - -

Tags: , ,

CBD Seizure Drug Considered Effective Following FDA-Recognized Trials

A new study published in the New England Journal of Medicine confirms what many patients, parents, advocates, and physicians already know – CBD reduces seizures. According to a Forbes report outlining the study, researchers found that patients with Dravet syndrome receiving CBD treatment experienced half the median seizure rate of the baseline rates from 12.4 […]

Read More - -

Tags: ,

Big Pharma Positioning for Federal Approval of Cannabis Drugs

In my most recent publishing, I wrote that our hemp/CBD industry was being hijacked from us. “Us,” being those who have fought against the establishment (Government, the law, Big Business, corrupt officials, and those who have financial gain in opposing any cannabis resurgence) to legalize a plant that is embedded into the very fabric of […]

Read More - -

Tags: , , , ,

Hemp CBD Companies Should Worry About FDA, Not DEA, Intervention

It’s been nearly two months since mainstream media outlets and several cannabis publications published headlines claiming that the Drug Enforcement Administration (DEA) was rescheduling cannabidiol (CBD) into a Schedule 1 substance and that some serious, Drug War-era crackdowns were coming. We reported then, and stand by our coverage, that this is not the case. The DEA […]

Read More - -

Tags: , , ,

Trump Considering Cannabis Advocate for FDA Commissioner

President Donald Trump has been announcing his nominations for the various positions in his administration since securing the election in November. Many of his choices have sparked concern among members of the cannabis industry, but one potential individual could have the opposite effect. Recently, the Trump team met with two potential candidates for FDA Commissioner, one […]

Read More - -

Tags:

You are viewing cannabis news and information related to FDA. View all cannabis news >>